Premium
Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways
Author(s) -
Eriksson Kerstin,
Magnusson Peetra,
Dixelius Johan,
Claesson-Welsh Lena,
Cross Michael J
Publication year - 2003
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(03)00003-6
Subject(s) - angiostatin , signal transduction , intracellular , microbiology and biotechnology , endostatin , fibroblast growth factor , chemistry , endothelial stem cell , vegf receptors , angiogenesis , biochemistry , biology , cancer research , receptor , in vitro
The anti‐angiogenic agents angiostatin and endostatin have been shown to affect endothelial cell migration in a number of studies. We have examined the effect of these agents on intracellular signalling pathways known to regulate endothelial cell migration and proliferation/survival. Both agents inhibited fibroblast growth factor (FGF)‐, and vascular endothelial growth factor (VEGF)‐mediated migration of primary human microvascular endothelial cells and affected vascular formation in the embryoid body model. However, using phosphospecific antibodies we could not detect any effect of angiostatin or endostatin on phospholipase C‐γ (PLC‐γ), Akt/PKB, p44/42 mitogen‐activated protein kinase (MAPK), p38 MAPK and p21‐activated kinase (PAK) activity. Furthermore, using a glutathione S‐transferase (GST)‐PAK pull‐down assay, we could not detect any effect on Rac activity. We conclude that angiostatin and endostatin inhibit chemotaxis, without affecting intracellular signalling pathways known to regulate endothelial migration and proliferation/survival.